Mechelen, Belgium; 14  January 2009 -  Galapagos NV (Euronext:  GLPG)
announced today achievement of multiple milestones under its alliance
with Janssen Pharmaceutica NV  ('Janssen').  Through the  achievement
of the milestone  payments announced today  Galapagos will receive  a
total of ?3.75 million.

In October  2007,  Galapagos  announced an  alliance  agreement  with
Janssen providing Janssen  with option rights  to acquire  worldwide,
commercial licenses  to  novel  small-molecules  from  up  to  12  of
Galapagos' internal  programs  involving  rheumatoid  arthritis  (RA)
therapeutic  targets.   The  milestones  announced  today  relate  to
achievement of  Proof of  Principle for  compounds developed  against
Galapagos targets.   The compounds  demonstrated  a reduction  of  an
inflammatory disease biomarker in inflamed joint tissue cultured from
collagen-induced arthritic  mice.   Showing  a reduction  in  such  a
disease marker is an important step in the development of a new drug,
indicating that the potential drug can  have an impact on slowing  or
reversing disease.

About Galapagos
Galapagos (Euronext Brussels: GLPG;  Euronext Amsterdam: GLPGA;  OTC:
GLPYY) is a drug discovery company with pre-clinical programs in bone
and joint diseases  and bone metastasis.   Its division BioFocus  DPI
offers a full suite of target-to-drug discovery products and services
to  pharmaceutical   and  biotech   companies,  encompassing   target
discovery and  validation, screening  and drug  discovery through  to
delivery of  pre-clinical  candidates.  BioFocus  DPI  also  provides
adenoviral reagents for rapid identification and validation of  novel
drug targets, compound libraries for drug screening as well as  ADMET
products to select compounds.  Galapagos currently employs 460 people
and operates facilities in six countries, with global headquarters in
Mechelen, Belgium.  More information about Galapagos can be found  at
www.glpg.com.


CONTACT

Galapagos NV
Graham Dixon, PhD
Senior Vice President Drug Discovery
+32 473 86 87 51
ir@glpg.com

This  release  may  contain  forward-looking  statements,  including,
without  limitation,  statements  containing  the  words  "believes,"
"anticipates," "expects," "intends,"  "plans," "seeks,"  "estimates,"
"may," "will,"  "could," "stands  to," and  "continues," as  well  as
similar expressions.   Such  forward-looking statements  may  involve
known and unknown risks, uncertainties and other factors which  might
cause  the  actual  results,  financial  condition,  performance   or
achievements of  Galapagos, or  industry  results, to  be  materially
different from any historic or future results, financial  conditions,
performance  or   achievements   expressed   or   implied   by   such
forward-looking statements.  Given these uncertainties, the reader is
advised not  to  place any  undue  reliance on  such  forward-looking
statements.  These forward-looking  statements speak only  as of  the
date of publication of this document.  Galapagos expressly  disclaims
any obligation to update any such forward-looking statements in  this
document to  reflect  any  change in  its  expectations  with  regard
thereto or any change in events, conditions or circumstances on which
any such statement is based, unless required by law or regulation.


This announcement was originally distributed by Hugin. The issuer is 
solely responsible for the content of this announcement.



Copyright © Hugin AS 2009. All rights reserved.